SymbolO6Z
NameLONZA GROUP LTD
SectorUNDEFINED
RegionUNDEFINED
Industry-
AddressMuenchensteinerstrasse 38 CH-4002 Basel Switzerland
Telephone+41 61 316 8111
Fax+41 61 316 9111
Email-
Websitehttps://www.lonza.com
IncorporationOTHERS
Incorporated On16 Mar 1999
Employees-
Fiscal Year-
Public Since-
ExchangesSGX
AuditorDELOITTE LTD, ZURICH (CH)
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description


Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and
has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.
Lonza is a supplier to the pharmaceutical, healthcare and life sciences
industries with products and services spanning from research to final product
manufacture to meet customers’ needs. The products Lonza manufacture for the
life sciences industry can be characterised as very complex molecules which are
manufactured in a highly regulated environment and will end up in the body of
human beings or animals.
Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and
biotechnology industries. The Group has strong capabilities in large and small
molecules, peptides, amino acids and niche bioproducts which play an important
role in the development of novel medicines and healthcare products. The Group
provides cell-based research, endotoxin detection and cell therapy
manufacturing. The Group is also a provider of high value chemicals and biotech
ingredients to the nutrition, hygiene, preservation, agro and personal care
markets.
To provide optimal support to its customers, the Group is organized into three
business divisions, namely, Custom Manufacturing, Life Science Ingredients and
Bioscience, which focus on specific sets of customers and their needs.

Additional info from SGX:

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and
has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.
Lonza is a supplier to the pharmaceutical, healthcare and life sciences
industries with products and services spanning from research to final product
manufacture to meet customers’ needs. The products Lonza manufacture for the
life sciences industry can be characterised as very complex molecules which are
manufactured in a highly regulated environment and will end up in the body of
human beings or animals.
Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and
biotechnology industries. The Group has strong capabilities in large and small
molecules, peptides, amino acids and niche bioproducts which play an important
role in the development of novel medicines and healthcare products. The Group
provides cell-based research, endotoxin detection and cell therapy
manufacturing. The Group is also a provider of high value chemicals and biotech
ingredients to the nutrition, hygiene, preservation, agro and personal care
markets.
To provide optimal support to its customers, the Group is organized into three
business divisions, namely, Custom Manufacturing, Life Science Ingredients and
Bioscience, which focus on specific sets of customers and their needs.

2026-06-09 05:01

Lonza Appoints Hans Trees as Global Head of Communications

Read more
2026-05-14 09:32

General Announcement: Purchase of Lonza Shares by a non-executive member of the board of directors

Read more
2026-05-14 09:32

General Announcement: Purchase of Lonza Shares by a non-executive member of the board of directors

Read more
2026-05-11 10:40

Mandatory Cash Dividend/ Distribution:

Read more
2026-05-11 10:37

Mandatory Cash Dividend/ Distribution:

Read more
2026-05-08 14:16

Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved

Read more
2026-05-08 05:00

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt

Read more
2026-05-08 04:31

Lonza Delivers Strong Performance in Q1 2026 in Line with Expectations and Confirms Full-Year Outlook 2026

Read more
2026-05-08 04:30

General Announcement: Lonza1 Delivers Strong Q1 2026 Performance in Line with Expectations and Confirms Full-Year Outlook

Read more
2026-05-08 04:01

Request for Trading Halt: Request for Trading Halt

Read more